Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Voxelotor - Global Blood Therapeutics

Drug Profile

Voxelotor - Global Blood Therapeutics

Alternative Names: GBT-440; GTx-011; Oxbryta

Latest Information Update: 16 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Global Blood Therapeutics
  • Developer Global Blood Therapeutics; Pfizer
  • Class Antianaemics; Antifibrotics; Benzaldehydes; Ethers; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Sickle haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sickle cell anaemia
  • Discontinued Hypoxia; Idiopathic pulmonary fibrosis

Most Recent Events

  • 29 Apr 2024 Pfizer suspends a phase II trial in Sickle cell anaemia (In adolescents, In children, In infants) in Lebanon and USA (PO) (NCT02850406)
  • 09 Dec 2023 Efficacy and adverse events data from a phase III trial in Sickle cell anaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 04 Oct 2023 Pfizer completes a phase I drug-drug interaction trial for Sickle cell anaemia in USA (PO, Tablet) (NCT05981365)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top